Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Investigational Drug May Reduce Involuntary Movements in People With Parkinson’s Disease

April 12, 2011 By Bio-Medicine.Org

HONOLULU, April 12, 2011 /PRNewswire-USNewswire/ — Results of
the first randomized, placebo-controlled long-term clinical trial
show the investigational drug safinamide may reduce dyskinesia or
involuntary movements in mid-to-late stage Parkinson’s disease. The
findings will be presented as late-breaking research at the 63rd
Annual Meeting of the American Academy of Neurology, April
9–16, 2011, in Honolulu.

“Our findings over a two-year treatment period suggest that
taking safinamide in addition to levodopa and other dopaminergic
treatments could help patients who continue to experience tremors
and involuntary movement problems,” said study author Ravi Anand,
MD, a consultant with Newron Pharmaceuticals in Bresso, Italy.
“These results are an important step forward in understanding how
safinamide impacts patients with severe Parkinson’s disease.
Symptoms of Parkinson’s disease, motor fluctuations and dyskinesia
can greatly affect a person’s daily living and quality of
life.”

For the two-year study, 669 patients with mid-to-late stage
Parkinson’s disease who were already taking levodopa and other
dopaminergic treatments were given 50 or 100 milligrams of
safinamide per day or a placebo pill. Scientists tested
participant’s movement ability using the United Parkinson’s disease
rating scale that measures activities such as tremor, speech,
behavior, mood and daily activities including swallowing, dressing
and walking. A specific tool measuring severity of dyskinesia (DRS)
was used in addition as primary efficacy endpoint.

At the start of the study, patients who took the 50 milligram
dose of safinamide had an average score of 3.9 compared to a score
of 3.4 for those taking a placebo pill. Patients who took the 100
milligram dose had an average score of 3.7.

After two years, researchers discovered in a post-hoc analysis
that safinamide at 100 milligrams a day on top of taking levodopa
reduced dyskines

‘/>”/>

SOURCE

Related Articles Read More >

A rat holding its face with its paws
Ultrasound research with rats shows potential for depression therapy
Tivic Health CEO Jennifer Ernst
Sinus pain is just the beginning for Tivic Health’s CEO
A series of before-and-after brain scans showing improvement in long COVID patients after hyperbaric oxygen therapy
Long COVID study finds potential in hyperbaric oxygen therapy
microrobot-purdue-university
This microrobot device could remove brain hemorrhages caused by stroke

DeviceTalks Weekly.

August 5, 2022
DTW Medtronic's Greg Smith lays out supply chain strategies
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech